The Australian government has awarded Victoria-based Lachesis Biosciences AUS$438,000 for commercialization of the company’s rivastigmine nasal spray for the treatment of dementia in patients with Alzheimer’s Disease. The Accelerating Commercialisation grant is designed to”help businesses turn good ideas into marketable products through activities such as trials, upscaling and connecting with new markets.”
In March 2017, Lachesis published bioavailability data from a PK study of intranasal rivastigmine in healthy volunteers in the British Journal of Clinical Pharmacology.
Read the Australian Department of Industry, Innovation, and Science announcement.
